Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset - PubMed (original) (raw)

. 1999 Dec;26(12):2562-71.

Affiliations

PMID: 10606363

Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset

S Wållberg-Jonsson et al. J Rheumatol. 1999 Dec.

Abstract

Objective: To identify predictors for cardiovascular disease (CVD) and for overall survival in patients with rheumatoid arthritis (RA) followed from disease onset.

Methods: A retrospective cohort of patients with seropositive RA and disease onset between 1974 and 1978 (n = 211) was followed up at the end of 1995. Potential predictors for CVD, as measured by "the first cardiovascular event," and for overall survival were registered. The predictors were identified by extended Cox regression models.

Results: In simple Cox regression analysis, male sex, higher age at disease onset, HLA-B27, high disease activity, corticosteroid treatment early in disease, and hypertension significantly increased risk of cardiovascular event. Higher educational level, extensive disease modifying antirheumatic drug (DMARD) treatment, and corticosteroids > or =1 yr before event decreased the risk. In multiple Cox regression analysis, male sex, high age at disease onset, hypertension, higher haptoglobin level at disease onset, and corticosteroid treatment early in disease increased risk of CVD. In a multiple model comprising only patients with CVD, corticosteroids delayed the event. A high last registered erythrocyte sedimentation rate (ESR) value before event increased CVD risk, in particular when early in disease progression. Decreased life span was predicted by higher age at disease onset, male sex, low education level, high disease activity, hypertension, and CVD. HLA-B27 was associated with decreased life span, as was early, but not extensive corticosteroid treatment. DMARD treatment was associated with decreased mortality risk, as was the presence of joint prosthesis. In multiple regression, male sex, higher age at disease onset, atlantoaxial subluxation early in disease, hypertension, and cardiovascular event increased mortality. A high last registered ESR value before event or death added to that risk.

Conclusion: The study emphasizes the importance of inflammation as an important risk indicator for CVD and mortality in RA. The positive impact of disease activity reducing treatment on CVD risk and survival is suggested.

PubMed Disclaimer

Comment in

Risk of cardiovascular events and effect on mortality in patients with rheumatoid arthritis.
Nossent H. Nossent H. J Rheumatol. 2000 Sep;27(9):2282-3. J Rheumatol. 2000. PMID: 10990252 No abstract available.

Cited by

Prevalence and factors related to left ventricular systolic dysfunction in asymptomatic patients with rheumatoid arthritis. A prospective tissue Doppler echocardiography study.
Cioffi G, Viapiana O, Ognibeni F, Dalbeni A, Gatti D, Adami S, Mazzone C, Faganello G, Di Lenarda A, Rossini M. Cioffi G, et al. Herz. 2015 Nov;40(7):989-96. doi: 10.1007/s00059-015-4320-5. Epub 2015 May 20. Herz. 2015. PMID: 25990626
Vascular disease as a cause of death in patients with severe disability due to osteoarthritis and rheumatoid arthritis.
Smith AM, Lingard L, Heslop P, Gray J, Walker DJ. Smith AM, et al. Springerplus. 2015 Jul 8;4:328. doi: 10.1186/s40064-015-1108-2. eCollection 2015. Springerplus. 2015. PMID: 26180748 Free PMC article.
Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis.
van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, Twisk JW, van de Stadt RJ, de Koning MH, Habibuw MR, van der Horst-Bruinsma IE, Dijkmans BA. van Halm VP, et al. Ann Rheum Dis. 2007 Feb;66(2):184-8. doi: 10.1136/ard.2006.051672. Epub 2006 Jun 7. Ann Rheum Dis. 2007. PMID: 16760255 Free PMC article.
Diastolic heart function in RA patients.
Wislowska M, Jaszczyk B, Kochmański M, Sypuła S, Sztechman M. Wislowska M, et al. Rheumatol Int. 2008 Apr;28(6):513-9. doi: 10.1007/s00296-007-0473-8. Epub 2007 Oct 24. Rheumatol Int. 2008. PMID: 17957370
Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study.
Dessein PH, Joffe BI, Stanwix AE. Dessein PH, et al. Arthritis Res. 2002;4(6):R12. doi: 10.1186/ar597. Epub 2002 Sep 16. Arthritis Res. 2002. PMID: 12453315 Free PMC article. Clinical Trial.

Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset - PubMed (original) (raw)